In bid to ad­vance man­u­fac­tur­ing ca­pa­bil­i­ties, In­scrip­ta buys out two biotechs

A life sci­ences com­pa­ny just bought out two syn­thet­ic bi­ol­o­gy com­pa­nies to add to its man­u­fac­tur­ing ar­se­nal.

Genome en­gi­neer and syn­bio out­fit In­scrip­ta put out word Wednes­day that it ac­quired In­fi­nome Bio­sciences and Ses­ti­na Bio to ad­vance In­scrip­ta’s strat­e­gy of de­vel­op­ing and com­mer­cial­iz­ing bio-man­u­fac­tured prod­ucts in a va­ri­ety of mar­kets.

Be­fore the ac­qui­si­tion, In­fi­nome was af­fil­i­at­ed with In­scrip­ta — the for­mer de­vel­oped its pro­pri­etary strain en­gi­neer­ing plat­form us­ing In­scrip­ta’s tech. In­fi­nome co-founder and CEO Richard Fox said in a press re­lease that com­bin­ing the two com­pa­nies brings a “shared vi­sion” to­geth­er of scal­able and sus­tain­able so­lu­tions for bio­man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER